Evidence map›Paper›PMID 27396933›Full record

ArticleHuman pathology2016

Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.

Christos G Tsokos, Gregor Krings, Funda Yilmaz, Linda D Ferrell, Ryan M Gill

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Cholangiocarcinoma.Pathologica · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christos G TsokosDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143-0102.
Gregor KringsDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143-0102.
Funda YilmazDepartment of Pathology, University of Ege Faculty of Medicine, Bornova, 35100, Izmir, Turkey.
Linda D FerrellDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143-0102.
Ryan M GillDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143-0102. Electronic address: ryan.gill@ucsf.edu.
University of California, San Francisco · USEge University · TR

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Differentiation between benign and malignant lesions of the hepatic biliary tree may pose a diagnostic problem because well-differentiated intrahepatic cholangiocarcinoma may mimic biliary hamartoma, bile duct adenoma, or parenchymal extinction. We evaluated Ki-67 proliferative index and p53 status by immunohistochemical staining to aid in exclusion of cholangiocarcinoma. Fourteen biliary hamartomas, 21 bile duct adenomas, and 11 livers with parenchymal extinction were compared with 26 intrahepatic cholangiocarcinomas (16 well-differentiated and 10 moderately or poorly differentiated tumors). We found an increased proliferative index in intrahepatic cholangiocarcinomas compared with benign biliary lesions (average 23.0% in cholangiocarcinoma versus 1.4% in all benign biliary lesions, n = 26 versus n = 46, P < .001). No difference in average proliferative index was observed between well-differentiated and moderately/poorly differentiated cholangiocarcinomas (average 22.7% versus 23.3%, n = 16 versus n = 10, P = .92). Average proliferation indices of benign biliary lesions were uniformly low (biliary hamartoma, 1.2%; bile duct adenoma, 2%; parenchymal extinction, 0.5%). Most cholangiocarcinomas (23/26; 88.5%), but none of the benign lesions (0/46; 0%), had proliferative indices greater than 10%. Strong nuclear p53 immunohistochemical staining was only seen in cholangiocarcinomas (9/26; 34.6%) and not in benign biliary lesions (0/46; 0%), although many of the benign lesions showed weak to moderate staining. Immunohistochemical staining for Ki-67 facilitates distinction between benign and malignant lesions of the intrahepatic biliary tree, whereas p53 immunohistochemical staining is less helpful.

Indexed as

Cell ProliferationImmunohistochemistryAdultAgedAged, 80 and overBile Duct NeoplasmsBiliary Tract DiseasesCholangiocarcinomaDiagnosis, DifferentialFemaleHumansKi-67 AntigenMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsKi-67 AntigenTP53 protein, humanTumor Suppressor Protein p53Bile duct adenomaBiliary hamartomaCholangiocarcinomaKi-67Mib1Von Meyenburg complex

Identifiers

PMID27396933
PMCPMC5250508
OpenAlexW2463985342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.